Please use this identifier to cite or link to this item: https://doi.org/10.1158/1535-7163.MCT-12-0311
Title: Activation of IL-6R/JAK1/STAT3 signaling induces De Novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation
Authors: Kim, S.M.
Kwon, O.-J.
Hong, Y.K.
Kim, J.H.
Solca, F.
Ha, S.-J.
Soo, R.A. 
Christensen, J.G.
Lee, J.H.
Cho, B.C.
Issue Date: Oct-2012
Citation: Kim, S.M., Kwon, O.-J., Hong, Y.K., Kim, J.H., Solca, F., Ha, S.-J., Soo, R.A., Christensen, J.G., Lee, J.H., Cho, B.C. (2012-10). Activation of IL-6R/JAK1/STAT3 signaling induces De Novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Molecular Cancer Therapeutics 11 (10) : 2254-2264. ScholarBank@NUS Repository. https://doi.org/10.1158/1535-7163.MCT-12-0311
Abstract: The secondary T790M mutation in epidermal growth factor receptor (EGFR) is the major mechanism of acquired resistance to EGFR tyrosine kinase inhibitors (TKI) in non-small cell lung cancer (NSCLC). Although irreversible EGFR TKIs, such as afatinib or dacomitinib, have been introduced to overcome the acquired resistance, they showed a limited efficacy in NSCLC with T790M. Herein, we identified the novel de novo resistance mechanism to irreversible EGFR TKIs in H1975 and PC9-GR cells, which are NSCLC cells with EGFR T790M. Afatinib activated interleukin-6 receptor (IL-6R)/JAK1/STAT3 signaling via autocrine IL-6 secretion in both cells. Inhibition of IL-6R/JAK1/STAT3 signaling pathway increased the sensitivity to afatinib. Cancer cells showed stronger STAT3 activation and enhanced resistance to afatinib in the presence of MRC5 lung fibroblasts. Blockade of IL-6R/JAK1 significantly increased the sensitivity to afatinib through inhibition of afatinib-induced STAT3 activation augmented by the interaction with fibroblasts, suggesting a critical role of paracrine IL-6R/JAK1/STAT3 loop between fibroblasts and cancer cells in the development of drug resistance. The enhancement of afatinib sensitivity by inhibition of IL-6R/JAK1/STAT3 signaling was confirmed in in vivo PC9-GR xenograft model. Similar to afatinib, de novo resistance to dacomitinib in H1975 and PC9-GR cells was also mediated by dacomitinib-induced JAK1/STAT3 activation. Taken together, these findings suggest that IL-6R/JAK1/STAT3 signaling can be a potential therapeutic target to enhance the efficacy of irreversible EGFR TKIs in patients with EGFR T790M. ©2012 AACR.
Source Title: Molecular Cancer Therapeutics
URI: http://scholarbank.nus.edu.sg/handle/10635/116210
ISSN: 15357163
DOI: 10.1158/1535-7163.MCT-12-0311
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

122
checked on Jul 3, 2020

WEB OF SCIENCETM
Citations

117
checked on Jul 3, 2020

Page view(s)

152
checked on Jun 27, 2020

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.